Docoh
Loading...

PBIO Pressure Biosciences

We are a leader in the development and sale of innovative, broadly enabling, pressure-based platform solutions for the worldwide life sciences industry. Our solutions are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus has been in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology platform) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be acceptably preserved using existing non-thermal technologies.

Company profile

Ticker
PBIO
Exchange
CEO
Richard T. Schumacher
Employees
Incorporated
Location
Fiscal year end
Former names
BOSTON BIOMEDICA INC
SEC CIK
IRS number
42652826

PBIO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

1 Apr 21
13 Apr 21
31 Dec 21
Quarter (USD)
Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 94.75K 94.75K 94.75K 94.75K 94.75K 94.75K
Cash burn (monthly) (positive/no burn) 1.93K 272.92K 384.46K 368.76K 468.83K
Cash used (since last report) n/a 12.53K 1.77M 2.49M 2.39M 3.04M
Cash remaining n/a 82.22K -1.68M -2.4M -2.3M -2.95M
Runway (months of cash) n/a 42.6 -6.1 -6.2 -6.2 -6.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Dec 20 Peterson Jeffrey N COMMON STOCK Other Aquire J No No 1.55 1,241 1.92K 21,714
10 Dec 20 Schumacher Richard T Common Stock Other Aquire J No No 1.55 284 440.2 37,320
10 Dec 20 Pollack Kevin Common Stock Other Aquire J No No 1.55 662 1.03K 20,905
10 Dec 20 Mangiardi Vito J COMMON STOCK Other Aquire J No No 1.55 142 220.1 12,695
10 Dec 20 Urdea Michael S Common Stock Other Aquire J No No 1.55 653 1.01K 17,506

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 0 NEW
Opened positions 1 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 1K 0 NEW
Total shares 404 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Victory Capital Management 404 $1K NEW
Largest transactions
Shares Bought/sold Change
Victory Capital Management 404 +404 NEW

Financial report summary

?
Competition
Hub
Management Discussion
  • We had total revenue of $1,809,993, in the year ended December 31, 2019 as compared with $2,457,871 in the prior year, a 26% decrease. The decrease was due to a decrease in product sales and grant revenue.
  • Products, Services, and Other. Revenue from the sale of products and services was $1,809,993 in the year ended December 31, 2019 compared with $2,200,539 in the year ended December 31, 2018, an 18% decrease. Revenue included sales of both PBI and CS’s pressure-based products and sales of our new Barofold Contract Services. Sales of instrumentation decreased in 2019 by $765,101 or 54%, from $1,418,731 in 2018 to $653,630 in 2019. Sales of consumables were $298,385 for the year ended December 31, 2019 compared to $235,132 for the same period in 2018, an increase of $63,253 or 27%. Sales of Barofold Contract Services increased from $118,383 in 2018 to $380,800 in 2019. Products, Services, and Other Revenue included $59,456 from non-cash transactions in the current year while the prior year included non-cash transactions of $91,265. Revenue from non-cash transactions was recognized based on the carrying value of the assets involved per ASC 845.
  • Grant Revenue. During 2019, we recorded $0 of grant revenue as compared with $257,332 in 2018. In December 2014, the Company was awarded a $1,020,969 SBIR Phase II grant (2R44HG007136) from the National Human Genome Research Institute of the NIH, which expired in 2018.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: CWX, device, Hedging, lesser, MicroPestle, prohibited, Similarly, week
Removed: Arrangement, guaranteeing, imputed, personally, Registrant